Decoding the Multi-Gene Drivers of Rare Disease via Quantum Network Medicine

The rare disease therapeutics market reached $150B in 2024, with over 50% of new FDA approvals targeting rare conditions. EntangleBio sits at the center of this growth.

Our Translational Pipeline:

1. Rare Disease Diagnostics: Providing molecular answers for the 200M+ people globally who currently lack a diagnosis.
    
2. Variant-Pair Prioritization: Assisting clinical centers in interpreting "variants of unknown significance."
    
3. Drug Discovery & Repurposing: Identifying combinatorial therapeutic targets by mapping variant-pair disruptions to known pharmacological pathways.
    

Future Milestone: The construction of the Quantum Interactome Atlas—a curated dataset mapping genetic variant pairs to clinical phenotypes.